ERS Genomics and Aelian Biotechnology in screening platform licence agreement

19th February 2020
ERS Genomics Limited and Aelian Biotechnology have signed a license agreement granting Aelian access to ERS Genomic’' CRISPR/Cas9 patent portfolio to support Aelian’s commercial functional genomic screening platform in which it combines CRISPR/Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action. Aelian’s novel platform is applicable across a wide range of cell types, including primary cells, and broadens access to a wider range of complex phenotypes. Under the terms of the licence agreement, Aelian is now able to offer its technology worldwide to pharmaceutical and biotech companies seeking more effective therapies.